Discontinuation rates due to adverse events were 4.1%, 6.9%, 11.3%, with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 4.9% with placebo
Mice were treated every other day for a total of ten doses, with daily body weight and food intake measurements (schematic of study design Fig
The ability of this medication to induce and lower blood sugar levels suggests that it can provide additional benefits versus current therapies in the treatment of T2D and obesity
They are undertreated because trial populations have historically skewed male
Reporting Side Effects to Your GP or MHRA Clinical trial participants must report suspected adverse events to their trial team first
renal function in patients with pre-existing kidney disease